Alteogen Inc. Alteogen Inc.

Alteogen Inc.

196170

株式のランク #1739
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$174.43
時価総額
$12.14B
変化（1日）
5.32%
変化（1年）
-44.70%
国
KR
取引 Alteogen Inc. (196170)

カテゴリー

Healthcare
Alteogen Inc.（196170）の株式分割履歴
Alteogen Inc.株（シンボル：196170）は合計で5回の株式分割を実施しました。
最新の株式分割はAug 05, 2026に行われました。
Dec 07, 2017より前に購入された196170株は、現在1.2037037037037196170株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
2026-08-05 13:10 x1.3 x1.2037037037037
2022-10-25 6:5 x1.2 x0.92592592592593
2021-03-24 5:4 x1.25 x0.77160493827161
2020-07-23 10:9 x1.1111111111111 x0.61728395061728
2017-12-07 5:9 x0.55555555555556 x0.55555555555556
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 1 x100
BE